Drug intelligence / Profile preview

SIM0CMX

Development stage: Preclinical
Lead developer: Simcere Pharmaceutical Group
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics

Overview

SIM0CMX is an investigational bispecific antibody being developed by Shandong Simcere Medgenn, a subsidiary of Simcere Pharmaceutical, for the treatment of oncological malignancies. As a T-cell engager, SIM0CMX is designed to bind simultaneously to the CD3 receptor on T cells and a specific tumor-associated antigen on cancer cells, thereby facilitating the formation of an immunological synapse and subsequent T-cell-mediated cytotoxicity. The drug is currently in the early stages of development within Simcere's oncology pipeline, specifically categorized within their CD3-bispecific antibody programs.

Targets

CD3 (T-cell surface glycoprotein CD3)

Beyond the preview

Go deeper on SIM0CMX.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SIM0CMX.

Explore the full profile